Pure Global
NCT00953914

Pyridostigmine and Its Effects on Autonomic Modulation in Diabetic Patients

Pyridostigmine and Its Effects on Autonomic Modulation in Diabetic Patients With Autonomic Neuropathy
Hospital de Clinicas de Porto Alegre·ClinicalTrials.gov·drugCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Diabetes Complications
Drug/Device/Intervention
Pyridostigmine
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Hospital de Clinicas de Porto Alegre
Location
Porto Alegre, Brazil
Timeline & enrollment
Phase
N/A
Start date
Mar 01, 2005
End date
May 01, 2010
Enrollment
40 participants
Primary outcome

autonomic modulation assessed by heart rate variability

Summary

The purpose of the study is to determine if pyridostigmine bromide improves heart rate
 variability of type 2 diabetes mellitus subjects with cardiovascular autonomic neuropathy.

ICD-10 classifications
Unspecified diabetes mellitus without complicationsOther specified diabetes mellitus with other specified complicationsOther specified diabetes mellitus without complicationsUnspecified diabetes mellitus with other specified complicationsOther specified diabetes mellitus with unspecified complications
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT00953914
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT00953914 through Pure Global AI's free database. This phase not specified trial is sponsored by Hospital de Clinicas de Porto Alegre and is currently Completed. The study focuses on Diabetes Complications. Target enrollment is 40 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.